HCV patients were divided into two groups over a 12 month period. Group A received Peg-IFN-a 2b plus ribavirin plus L-carnitine, and Group B received Peg-IFN-a and ribavirin. Red cell count, hemoglobin, white cell count, platelets, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and viremia were tested in all subjects.
After 12 months, group A compared to group B differences were observed in AST, ALT, viremia, hemoglobin, red blood cells, white blood cells, and platelets. In group A compared to group B there was improvement of sustained virological response, while relapses were also fewer.
The researchers concluded, "L-carnitine supplementations may modulate erythropoiesis, leucopoiesis and thrombocytopoiesis, and may be useful in patients treated for HCV. L-carnitine treatment may have the potential to offer sustained virological response while preventing over treatment."
So the last two studies I covered would seem to suggest L-carnitine could be beneficial to those with various liver issues.
Source: L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin (full-text)
Related posts on L-carnitine:
- L-Carnitine May Reduce Inflammation in Hemodialysis Patients
- L-Carnitine May Protect Mitochondrial Function in Liver
- L-Carnitine May Reduce Oxidative Damage
- L-Carnitine Helps Treat Autism Spectrum Disorders
- L-Carnitine May Help Kids with Asthma
- L-Carnitine Benefits Huntington's Disease
Click HERE to subscribe to Know Guff by email